Video: ME-015 Mode of Action | Melius Pharma AB

top of page

Melius_Logo_Neon+Mist30%-on-Trans_RGB.png

Home
Diseases
Pipeline
About
Contact
More

Use tab to navigate through the menu items.

Two-minute explainer video
ME-015 Mode of Action

© 2024 About Melius Pharma AB

Site by Balanced Agency

Melius Pharma is a Swedish clinical-stage pharmaceutical company. We develop new treatments for chronic cough in Idiopathic Pulmonary Fibrosis (IPF).

Registered address:

MELIUS PHARMA AB, Stockholmsvägen 45c, 182 78 STOCKSUND. Sweden

SwedenBio_EN[4][1][42].png

Intellectual Property

Patent application covering the use of ME-015 for treatment of cough associated with interstitial lung diseases has been filed with priority from 23.12.2015

European patent granted on 20 January 2021
US patent in the process of being approved

Formulation patent filed with priority from 29.08.2017 and in national phase (EPO, US, KR, CN, CA, AU, IN).

Home
Diseases
Pipeline
About
Contact
More

Use tab to navigate through the menu items.

bottom of page